Toll-like receptors 3 (TLR3) have been broadly studied among all TLRs over the last few decades together with its agonists due to their contribution to cancer regression. These agonists undeniably have some shared characteristics such as mimicking dsRNA but pathways through which they exhibit antitumor properties are relatively diverse. In this review, three widely studied agonists RGC100, ARNAX, and poly-IC are discussed along with their structural and physiochemical differences including the signaling cascades through which they exert their actions. Comparison has been made to identify the finest agonist with maximum effectivity and the least side effect profile.

在过去的几十年里，Toll 样受体 3 (TLR3) 及其激动剂在所有 TLR 中被广泛研究，因为它们有助于癌症消退。不可否认，这些激动剂具有一些共同的特征，例如模仿 dsRNA，但它们表现出抗肿瘤特性的途径相对多样化。在这篇综述中，讨论了三种广泛研究的激动剂 RGC100、ARNAX 和 poly-IC，以及它们的结构和物理化学差异，包括它们发挥作用的信号级联。已进行比较以确定具有最大效力和最少副作用的最佳激动剂。